1
Most patients had combined modality treatment with surgery, chemotherapy and radiation therapy.
2
Survival appears similar to that seen with modern combined modality regimens.
3
This classification can be used in planning combined modality treatment for paravertebral sarcomas.
4
For patients with locally advanced tumors, combined modality treatment is undergoing rapid evolution.
5
Patients and methods: Thirty-one patients (group A) completed the combined modality regimen.
6
We close with some thoughts on future directions and best practices for combining modalities.
7
Preoperative combined modality therapy is an attractive approach in patients with unresectable rectal cancer.
8
Future efforts combining modalities that endow CTL with complimentary metabolic advantages should improve therapeutic efficacies.
9
Modern combined modality treatment has significantly improved overall survival.
10
In univariate analyses, statistically significant factors favorably influencing the outcome were early-stage and combined modality treatment.
11
Improvement of outcomes of this combined modality by developing novel radiosensitizers is a viable therapeutic strategy.
12
Combined modality therapy is needed for localized EC.
13
Although the combined modality arm is relatively well tolerated, it does result in more chemotherapy-associated toxic effects.
14
Combined modality treatment in locally advanced NSCLC continues to evolve and is the subject of ongoing research.
15
Recently, combined modality therapy has improved outcome in other subsets of locally advanced non-small cell lung carcinoma.
16
Future research directions will include development of more efficient vectors, use of novel genes, and combined modality approaches.